Addition of rifampin to cephalexin therapy for recalcitrant staphylococcal skin infections - An observation

Clinical Pediatrics

Volumn 35, Issue 4, 1996, Pages 205-208

  Feder Jr , Henry M ^a   Pond, Karen E ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFALEXIN; CLOXACILLIN; DICLOXACILLIN; RIFAMPICIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; CASE REPORT; CHILD; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; IMPETIGO BULLOSA; INTRAVENOUS DRUG ADMINISTRATION; SKIN INFECTION; SKIN ULCER; STAPHYLOCOCCUS INFECTION;

EID: 0030026705     PISSN: 00099228     EISSN: None     Source Type: Journal    
DOI: 10.1177/000992289603500405     Document Type: Article

References (16)

1. Finch R. Skin and soft-tissue infections. Lancet. 1988;1:164-168.
2. Feder HM Jr, Abrahamian LM, Grant-Kels JM. Is penicillin still the drug of choice for non-bullous impetigo? Lancet. 1991;338:803-805.
3. Hebert AA, Still JG, Reuman PD. Comparative safety and efficacy of clarithromycin and cefadroxil suspensions in the treatment of mild to moderate skin and skin structure infections in children. Pediatr Infect Dis J. 1993;12(Suppl.):112-117.
4. Tomasz A. Multiple-antibiotic-resistant pathogenic bacteria. N Engl J Med. 1994;330:1247-1251.
5. Kapusnik JE, Parenti F, Sande MA. The use of rifampin in staphylococcal infections - a review. J Antimicrob Chemother. 1984;13(Suppl.):61-66.
6. Tsankov NK, Kamarashev JA. Rifampin in dermatology. Int J Derm 1993;32:401-406.
7. Farr B, Mandell GL. Rifampin. Med Clin North Am. 1982;66:157-165
8. Morris AB, Brown RB, Sands M. Use of rifampin in nonstaphylococcal, nonmycobacterial disease. Antimicrob Agents Chemother. 1993;37:1-7.
9. Traczewski MM, Goldmann DA, Murphy P. In vitro activity of rifampin in combination with oxacillin against Staphylococcus aureus. Antimicrob Agents Chemother. 1983;23.571-576.
10. VanDerAuwera P, Klastersky J. In vitro study of combination of rifampin with oxacillin against Staphylococcus aureus. J Inf Dis. 1983;5(Suppl.):509-513.
11. VanDerAuwera P, Meunier-Carpentier F, Klastersky J. Clinical study of combination therapy with oxacillin and rifampin for staphylococcal infections. Rev Inf Dis. 1983;5(Suppl.):515-522.
12. Grosset J, Leventis S. Adverse effects of rifampin. Rev Infect Dis. 1983; 5(Suppl.):440-444.
13. Sande MA. The use of rifampin in the treatment of nontuberculous infections: an overview. Rev Inf Dis. 1983;5(Suppl.):339-401.
14. Chaudhary S, Bilinsky SA, Hennessy JL, et al. Penicillin V and rifampin for the treatment of group A streptococcal pharyngitis: a randomized trial of 10 days of penicillin vs 10 days of penicillin with rifampin during the final 4 days of therapy. J Pediatr. 1985; 106:481-486.
15. Tanz RR, Shulman ST, Barthel MJ, et al. Penicillin plus rifampin eradicates pharyngeal carriage of group A streptococci. J Pediatr. 1985;106:876-880.
16. Tan TQ, Mason EO Jr, Ou C, Kaplan SL. Use of intravenous rifampin in neonates with persistent staphylococcal bacteremia. Antimicrob Agents Chemother. 1993;37:2401-2406.